Type I Interferons in Autoimmunity: Implications in Clinical Phenotypes and Treatment Response. Review uri icon

Overview

abstract

  • Type I interferon (IFN-I) is thought to play a role in many systemic autoimmune diseases. IFN-I pathway activation is associated with pathogenic features, including the presence of autoantibodies and clinical phenotypes such as more severe disease with increased disease activity and damage. We will review the role and potential drivers of IFN-I dysregulation in 5 prototypic autoimmune diseases: systemic lupus erythematosus, dermatomyositis, rheumatoid arthritis, primary Sjögren syndrome, and systemic sclerosis. We will also discuss current therapeutic strategies that directly or indirectly target the IFN-I system.

publication date

  • July 1, 2023

Research

keywords

  • Autoimmune Diseases
  • Interferon Type I
  • Lupus Erythematosus, Systemic

Identity

Scopus Document Identifier

  • 85169624454

Digital Object Identifier (DOI)

  • 10.3899/jrheum.2022-0827

PubMed ID

  • 37399470

Additional Document Info

volume

  • 50

issue

  • 9